Considering the findings in this study, coupled with the anti-inflammatory effect of type I IFN, type-I IFN-mannosylated albumin fusion protein is not a treatment to directly remove the causes, but is expected to exert therapeutic effects on liver diseases such as viral hepatitis, alcoholic hepatitis, and NASH. The gene discussed is ALB; the disease is alcoholic hepatitis.